1. Home
  2. TNGX vs IMTXW Comparison

TNGX vs IMTXW Comparison

Compare TNGX & IMTXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TNGX
  • IMTXW
  • Stock Information
  • Founded
  • TNGX 2014
  • IMTXW N/A
  • Country
  • TNGX United States
  • IMTXW Germany
  • Employees
  • TNGX N/A
  • IMTXW 343
  • Industry
  • TNGX Biotechnology: Pharmaceutical Preparations
  • IMTXW Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • TNGX Health Care
  • IMTXW Health Care
  • Exchange
  • TNGX Nasdaq
  • IMTXW Nasdaq
  • Market Cap
  • TNGX 990.5M
  • IMTXW N/A
  • IPO Year
  • TNGX N/A
  • IMTXW N/A
  • Fundamental
  • Price
  • TNGX $9.75
  • IMTXW $3.43
  • Analyst Decision
  • TNGX Strong Buy
  • IMTXW
  • Analyst Count
  • TNGX 8
  • IMTXW 0
  • Target Price
  • TNGX $14.86
  • IMTXW N/A
  • AVG Volume (30 Days)
  • TNGX 851.2K
  • IMTXW N/A
  • Earning Date
  • TNGX 08-05-2024
  • IMTXW N/A
  • Dividend Yield
  • TNGX N/A
  • IMTXW N/A
  • EPS Growth
  • TNGX N/A
  • IMTXW N/A
  • EPS
  • TNGX N/A
  • IMTXW N/A
  • Revenue
  • TNGX $37,232,000.00
  • IMTXW N/A
  • Revenue This Year
  • TNGX N/A
  • IMTXW N/A
  • Revenue Next Year
  • TNGX $2.40
  • IMTXW N/A
  • P/E Ratio
  • TNGX N/A
  • IMTXW N/A
  • Revenue Growth
  • TNGX 49.72
  • IMTXW N/A
  • 52 Week Low
  • TNGX $2.88
  • IMTXW N/A
  • 52 Week High
  • TNGX $13.03
  • IMTXW N/A
  • Technical
  • Relative Strength Index (RSI)
  • TNGX 57.31
  • IMTXW N/A
  • Support Level
  • TNGX $8.93
  • IMTXW N/A
  • Resistance Level
  • TNGX $9.96
  • IMTXW N/A
  • Average True Range (ATR)
  • TNGX 0.60
  • IMTXW 0.00
  • MACD
  • TNGX -0.01
  • IMTXW 0.00
  • Stochastic Oscillator
  • TNGX 82.57
  • IMTXW 0.00

About TNGX Tango Therapeutics Inc.

Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.

About IMTXW Immatics N.V.

Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.

Share on Social Networks: